by mpzzqmvj | Sep 8, 2021 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
by mpzzqmvj | Aug 17, 2021 | Press Releases
– Solid clinical and operational execution demonstrated with advancement of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) with commencement of pivotal study (TransportNPC™) and start of commercial-scale manufacturing –...
by mpzzqmvj | Jul 30, 2021 | Press Releases
– Data seen to-date in the ongoing Phase 1 extension study provide additional support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions in Niemann-Pick Disease Type C1 (“NPC”)-...
by mpzzqmvj | Jul 27, 2021 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
by mpzzqmvj | Jun 21, 2021 | Press Releases
Company to discuss clinical progress of Trappsol® Cyclo™ development program for the treatment of Niemann-Pick Disease Type C (NPC) GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the...
